Future Capital AG is an independent private equity growth and expansion fund based in Frankfurt, Germany. Established in March 1999 through the initiative of the Hessen State Government and Hoechst AG, the fund focuses on investing in companies within the life sciences, pharmaceuticals, biotechnology, chemistry, nanotechnology, and material sciences sectors. Future Capital manages assets totaling € 51 million and typically invests between € 0.75 million and € 10 million in each company.
EKuaibao offers an online platform for enterprise consumption and reimbursement management, targeting corporate claims and expense management challenges. The platform is designed to assist businesses in effectively managing employee cost reimbursements, business travel planning, and overall expense control. By providing innovative invoice management solutions, EKuaibao aims to help organizations reduce operational costs and enhance efficiency. The company's focus on professional ordering and comprehensive reimbursement services makes it a valuable resource for enterprises seeking to streamline their financial processes.
Megarobo
Corporate Round in 2021
Megarobo is an AI and robotics company established in 2016 and headquartered in Beijing, China. It specializes in developing collaborative robots and advanced automation solutions tailored for life sciences, clinical diagnosis, and applied chemistry. By focusing on integrating robotics and artificial intelligence into industry applications, Megarobo aims to enhance research efficiency for life science companies and scientific research institutions. The company is dedicated to providing flexible and practical automation products that streamline laboratory services, ultimately driving innovation in the field of scientific research.
Duckbill
Venture Round in 2021
Duckbill provides container trucking transportation services, international freight forwarding, and warehousing services by using big data and AI.
Bishi Technology
Series B in 2020
Bishi Technology is a tech enterprise in the field of intelligent operation and maintenance, Biztech has always been committed to providing enterprise users with easy-to-use and stable intelligent operation and maintenance products. Biz intelligent operation and maintenance platform is based on machine learning algorithms, helping large enterprise data centers to find faults in advance, locate fault ranges, predict trends in massive monitoring data, reduce mean time to repair (MTTR) and prolong system trouble-free running time (MTBF) , improve system availability and operation and maintenance efficiency.
Duckbill
Series B in 2020
Duckbill provides container trucking transportation services, international freight forwarding, and warehousing services by using big data and AI.
Aignostics
Seed Round in 2020
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
ClickPaaS China
Series A in 2019
ClickPaaS is a provider of low code development platform products and solutions based on hpaPaaS that helps SaaS enterprises, consulting firms, and enterprise customers to significantly reduce response times and costs for complex business requirements. ClickPaaS is an innovative technology platform company dedicated to the development and service of the highly productive aPaaS platform, providing fast, high-quality technology platforms for government companies, consulting companies, startups and professional partners.
Ruixun Biotech
Series A in 2019
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
RainSure Scientific
Series A in 2019
RainSure Scientific is a medical-based manufacturing company that produces PCR instruments, assays, and healthcare services.
Li Auto
Series B in 2018
Li Auto Inc. is a prominent Chinese manufacturer of smart electric vehicles, specializing in the design, development, production, and sale of premium electric sport utility vehicles (SUVs). Established in 2015 and headquartered in Beijing, the company launched its first model, the Li ONE, in November 2019. This six-seat electric SUV features a range extension system and advanced smart vehicle solutions, catering to consumers seeking longer travel capabilities. In 2023, Li Auto sold over 376,000 new energy vehicles, capturing approximately 4% of China's passenger new energy vehicle market. The company continues to expand its product offerings, including battery electric vehicles (BEVs) and plug-in hybrid electric vehicles (PHEVs), in order to reach a wider audience and meet diverse consumer needs.
ZVISION
Angel Round in 2018
Zvision provides automotive-grade solid-state LiDAR solution for autonomous driving applications. The company's first-generation laser radar products use MEMS technology, and plan to achieve scale-up in the L3-class autonomous driving and unmanned logistics fields in the next five years, and layout the next generation optical-based phased array (OPA) through its integrated chip research and development capabilities. The technical laser radar is aimed at the L4/L5 level autopilot market after 5-10 years.
Miss Evan
Series A in 2017
Missevan is a prominent domestic secondary audio community that specializes in pop culture entertainment. The company offers a social platform for designers and artists to share and distribute a diverse range of 2D media, including audio comic series, live broadcasting shows, original music, audiobooks, and ringtone designs. Through its platform, Missevan facilitates engagement and collaboration among creators while providing users with access to a variety of entertainment content.
Yihang.ai
Angel Round in 2016
Yihang.ai specializes in developing autonomous driving systems, providing a comprehensive auto-driving solution known as AutoPilot. Established in 2015 and headquartered in Beijing, the company focuses on high reliability, quality, and cost-effectiveness in its products. Yihang.ai has successfully commercialized its Autopilot function, which incorporates advanced algorithms and deep learning technologies to enhance automotive control systems, thereby reducing driver burden and improving safety. The company's expertise lies in artificial intelligence, particularly in sensing, decision-making, control, and fault diagnosis. Its team is composed of professionals from the automotive industry and experts in computer vision and deep learning, with backgrounds from both domestic and international original equipment manufacturers, Tier 1 suppliers, and prestigious academic institutions.
Nongfenqi
Series A in 2016
Nongfenqi is a rural internet finance services platform operated by Nanjing Nongfenqi E-Commerce Co. Ltd. It specializes in offering installment payment solutions for agricultural equipment purchases to large farming groups and collaborative communes. This financial service aims to facilitate agricultural operations by enabling farmers to acquire necessary equipment without the burden of upfront costs. To date, Nongfenqi has served approximately 20,000 clients, contributing to the modernization and efficiency of farming practices.
Ganymed Pharmaceuticals
Series E in 2013
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
Ganymed Pharmaceuticals
Series D in 2008
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
Ganymed Pharmaceuticals
Series C in 2007
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
Ganymed Pharmaceuticals
Series B in 2005
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
3-G International
Private Equity Round in 2000
3-G International, founded in 1982 and headquartered in Springfield, Virginia, specializes in developing software-based solutions for smart cards and biometric authentication. The company provides innovative security products designed to enhance internet and network security, as well as authentication in the e-commerce sector. By offering advanced card management solutions, 3-G International enables organizations to implement more secure access methods than traditional passwords for workstations, networks, and applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.